Gene Information
Gene symbol: CHEK2
Gene name: checkpoint kinase 2
HGNC ID: 16627
Synonyms: CDS1, CHK2, HuCds1, PP1425, bA444G7
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | ATM | 1 hits |
| 2 | BRCA1 | 1 hits |
| 3 | BRCA2 | 1 hits |
| 4 | BRD2 | 1 hits |
| 5 | BRIP1 | 1 hits |
| 6 | CDH1 | 1 hits |
| 7 | CYP1A1 | 1 hits |
| 8 | GSTA1 | 1 hits |
| 9 | MSH2 | 1 hits |
| 10 | MSH6 | 1 hits |
| 11 | MUTYH | 1 hits |
| 12 | NBN | 1 hits |
| 13 | PALB2 | 1 hits |
| 14 | PMS2 | 1 hits |
| 15 | RAD50 | 1 hits |
| 16 | TTR | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 33426465 | Patients (N=37 349) had RS results of whom 714 had <i>BRCA1</i>, <i>BRCA2</i>, <i>CHEK2</i>, <i>ATM</i>, <i>PALB2</i>, or Lynch syndrome (<i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i>) PVs. |
| 2 | 33426465 | For women aged 50 years or older at breast cancer diagnosis, RS often exceeded the chemotherapy benefit threshold (≥26) with <i>BRCA1</i> (71.7% vs 14.4% with none; <i>P</i> <.001), <i>PALB2</i> (37.1%; <i>P</i> = .001), and <i>BRCA2</i> (44.3%; <i>P</i> < .001) PVs. |
| 3 | 33426465 | PVs in <i>BRCA1</i>, but not <i>BRCA2</i>, <i>PALB2</i>, <i>ATM</i>, <i>CHEK2</i>, or Lynch syndrome genes, were associated with elevated RS on multivariable analysis (<i>P</i> < .001). |
| 4 | 33724863 | We used panel sequencing containing 22 high/moderate-risk susceptibility genes and parallel MLPA analysis of BRCA1/2, CHEK2 genes, to analyze 94 individuals with a strong family/personal history of breast and/or ovarian cancer. |
| 5 | 33724863 | We used panel sequencing containing 22 high/moderate-risk susceptibility genes and parallel MLPA analysis of BRCA1/2, CHEK2 genes, to analyze 94 individuals with a strong family/personal history of breast and/or ovarian cancer. |
| 6 | 33724863 | In total, we have identified 22 causal DNA variants (23.4%) showing 15 primary findings in BRCA1/2 genes (68.2%) and 7 positive secondary findings in CHEK2, PALB2, CDH1, and MUTYH genes (31.8%). |
| 7 | 33724863 | In total, we have identified 22 causal DNA variants (23.4%) showing 15 primary findings in BRCA1/2 genes (68.2%) and 7 positive secondary findings in CHEK2, PALB2, CDH1, and MUTYH genes (31.8%). |
| 8 | 33724863 | Besides known mutations, the BRCA1 variant c.2794del (p.Val932Leufs*68) and variant c.2480dup (p.Tyr827*) in the CDH1 gene represent the novel, previously unpublished variants that might be population-specific. |
| 9 | 33724863 | Besides known mutations, the BRCA1 variant c.2794del (p.Val932Leufs*68) and variant c.2480dup (p.Tyr827*) in the CDH1 gene represent the novel, previously unpublished variants that might be population-specific. |
| 10 | 33983592 | Susceptibility genes involved in disease etiology and prognosis are categorized into two groups: high penetrance genes (i.e., BRCA1, CHEK2, ATM, etc.) and low penetrance genes (i.e., NATs, GSTs, CYPs, etc., and variants identified by genome-wide association studies). |
| 11 | 34606975 | Hereditary breast and ovarian cancer (HBOC) is a syndrome defined by an increased risk of developing breast and/or ovarian cancer most commonly due to germline disease-causing variants in the BRCA1 and BRCA2 genes, but also other causative genes such as PALB2, ATM and CHEK2. |
| 12 | 35039564 | Since the discovery of the breast cancer susceptibility genes, BRCA1 and BRCA2, various other genes conferring an increased risk for breast cancer have been identified. |
| 13 | 35039564 | Studies to evaluate sequence variants in cancer predisposition genes among women of African ancestry are limited and mostly focused on BRCA1 and BRCA2. |
| 14 | 35039564 | With the exception of four cases, all others were previously investigated for BRCA1 and BRCA2 deleterious variants, and were negative for pathogenic variants. |
| 15 | 35039564 | A total of 3.6% of patients carried a pathogenic/likely pathogenic variant in a known breast cancer susceptibility gene: 1.2% in BRCA1, 0.6% in each of BRCA2, ATM, CHEK2 and PALB, none of whom had any family history of breast cancer. |
| 16 | 35039564 | The mean age of patients who carried deleterious variant in BRCA1/BRCA2 was 39 years and 8 months compared to 47 years and 3 months among women who carried a deleterious variant in other breast cancer susceptibility genes. |
| 17 | 17292821 | BRCA1 and BRCA2 mutations confer very high risks of breast and ovarian cancer. p53 and PTEN mutations lead to very high breast cancer risks associated with rare cancer syndromes. |
| 18 | 17292821 | Mutations in CHEK2, ATM, NBS1, RAD50, BRIP1, and PALB2 are associated with doubling of breast cancer risks. |
| 19 | 17292821 | In addition, biallelic mutations in BRCA2, BRIP1, and PALB2 cause Fanconi anemia. |